Generic placeholder image

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery


ISSN (Print): 1872-2148
ISSN (Online): 2212-3334

Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)

Author(s): Malgorzata E. Kiec-Klimczak, Dorota M. Pach, Magdalena E. Pogwizd and Alicja B. Hubalewska-Dydejczyk

Volume 5 , Issue 3 , 2011

Page: [176 - 182] Pages: 7

DOI: 10.2174/187221411797265863

Price: $65


Incretins, which are insulinotropic gastrointestinal hormones, are produced mainly in K and L cells of the small intestine under the influence of nutritional stimuli. The best known incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones perform several functions: they stimulate insulin secretion in the pancreatic beta cells; they inhibit glucagon release from the alpha cells of the pancreas (GIP not in humans); they slow down gastric emptying and may directly suppress appetite; and, moreover, they indirectly increase peripheral glucose tolerance/insulin sensitivity. The insulinotropic and glucagonostatic effects of GLP-1 are glucose dependent. The incretins also have numerous other properties which are still being discovered and introduced in different branches of medicine. The patents mentioned in this work concern the use of incretins in diabetology, cardiology, gastroenterology and nuclear medicine. The pleiotropic effects of incretins offer therapeutic possibilities in numerous fields of medicine.

Keywords: DPP-4, Incretin effect, Cardiovascular system, ion metabolism, GIP, GLP-1, incretin, carbohydrate metabolism, glucagon, Gastro-intestinal disorders, Central nervous system

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy